Abstract
Surface modified activated carbon with methanesulfonic acid (AC-MsOH) is found to catalyze [3+2] cycloaddition reactions between alkyl/aryl azides and nitroolefins which yielded regioselective 1,5-disubstituted-1,2,3-triazolines in high yields under mild conditions.
Keywords: Activated Carbon, [3+2] Cyclo-addition, 1, 2, 3-triazolines, nitroolefins.
Graphical Abstract
Current Organic Synthesis
Title:Specific Synthesis of 1,5-Disubstituted-1,2,3-triazolines Catalyzed by Surface Modified Activated Carbon with MsOH
Volume: 13 Issue: 1
Author(s): Nanjundaswamy Marishetty Hemmaragala and Heidi Abrahamse
Affiliation:
Keywords: Activated Carbon, [3+2] Cyclo-addition, 1, 2, 3-triazolines, nitroolefins.
Abstract: Surface modified activated carbon with methanesulfonic acid (AC-MsOH) is found to catalyze [3+2] cycloaddition reactions between alkyl/aryl azides and nitroolefins which yielded regioselective 1,5-disubstituted-1,2,3-triazolines in high yields under mild conditions.
Export Options
About this article
Cite this article as:
Marishetty Hemmaragala Nanjundaswamy and Abrahamse Heidi, Specific Synthesis of 1,5-Disubstituted-1,2,3-triazolines Catalyzed by Surface Modified Activated Carbon with MsOH, Current Organic Synthesis 2016; 13 (1) . https://dx.doi.org/10.2174/1570179412666150505184249
DOI https://dx.doi.org/10.2174/1570179412666150505184249 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Silico Design of Protein Kinase Inhibitors: Successes and Failures
Anti-Cancer Agents in Medicinal Chemistry Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Medicinal Chemistry and Emerging Strategies Applied to the Development of Selective Estrogen Receptor Modulators (SERMs)
Current Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design An Antileukemic Glutaminase Free L-Asparaginase from Bacillus brevis
Current Biotechnology Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Liposomal Nanotechnology for Cancer Theranostics
Current Medicinal Chemistry Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents